Clinical Trials Sponsored by Immune Targeting Systems Ltd

Total 10 results

Immune Targeting Systems Ltd

Completed

Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers

Influenza A

Belgium
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Immune Targeting Systems Ltd
Hammersmith Medicines Research

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

Influenza

United Kingdom
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Immune System Key Ltd

Withdrawn

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Israel
Immune System Key Ltd

Withdrawn

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Triple Negative Breast Cancer | Metastatic Ovarian Cancer

Israel
Immune System Key Ltd

Completed

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

Cancer

Israel
Georgetown University
Immune System Key Ltd

Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid Tumor | KRAS Mutation-Related Tumors

United States
Immune System Key Ltd
University of Miami Sylvester Comprehensive Cancer Center

Recruiting

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

AML | Advanced MDS

United States

3

Subscribe